WASHINGTON, DC 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                  Commission File Number 0-28498

(Check one)

|_| Form 10-K and Form 10-KSB   |_| Form 11-K

|_| Form 20-F  |X| Form 10-Q and Form 10-QSB  |_| Form N-SAR

For period ended: June 30, 2006

|_| Transition Report on Form 10-K and Form 10-KSB

|_| Transition Report on Form 20-F

|_| Transition Report on Form 11-K

|_| Transition Report on Form 10-Q and Form 10-QSB

|_| Transition Report on Form N-SAR

For the transition period ended _____________________________________________

Read Attached Instruction Sheet Before Preparing Form.  Please Print or Type.

         Nothing in this form shall be  construed  to imply that the  Commission
has verified any information contained herein.

         If the  notification  relates to a portion of the filing checked above,
identify the item(s) to which the notification relates__________________________

                                     PART I
                             REGISTRANT INFORMATION

Full name of registrant: Paradigm Medical Industries, Inc.

Former name if applicable: _____________________________________________________

Address of principal executive office (Street and number):

                           2355 South 1070 West
                           Salt Lake City, Utah 84119

                                     PART II
                             RULE 12b-25(b) AND (c)

         If the subject report could not be filed without unreasonable effort or
expense  and the  registrant  seeks  relief  pursuant  to Rule  132b-25(b),  the
following should be completed. (Check box if appropriate).

         (a)  The reasons  described  in  reasonable  detail in Part III of this
              form  could  not be  eliminated  without  unreasonable  effort  or

         |X|  (b) The subject  annual  report,  semi-annual  report,  transition
              report on Form 10-K,  Form 20-F,  11-K or Form  N-SAR,  or portion
              thereof,  will be filed on or before the  fifteenth  calendar  day
              following the prescribed due date; or the subject quarterly report
              of  transition  report on Form 10-Q,  or portion  thereof  will be
              filed on or before the fifth calendar day following the prescribed
              due date; and

         (c)  The  accountant's  statement  or other  exhibit  required  by Rule
              12(b)-25(c) has been attached if applicable.

                                    PART III

         State below in  reasonable  detail the  reasons  why Forms 10-K,  11-K,
10-Q,  N-SAR or the  transition  report or portion  thereof,  could not be filed
within the prescribed time period. (Attach extra sheets if needed.)

         The Form 10-QSB cannot be completed  within the prescribed  time period
due to the  additional  time required  because of the  complexities  involved in
completing the required financial statements,  particularly relating to the sale
of $1,500,000 in callable secured convertible notes.

                                     PART IV
                                OTHER INFORMATION

(1)      Name  and  telephone  number of  person  to  contact in  regard to this

          Randall A. Mackey                (801)               575-5000
          -----(name)-------------------(area code)-----(telephone number)------

(2)      Have all other periodic  reports required under  Section 13 or 15(d) of
the Securities Exchange  Act of 1934 or Section 30 of the Investment Company Act
of 1940  during the  preceding 12 months  (or for such shorter)  period that the
registrant was  required to  file such  report(s) been filed?   If answer is no,
identify report(s).

         |X|Yes    |_| No

(3)      Is it anticipated that any significant change in results of  operations
from  the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

If so, attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

         |_| Yes    |X| No

                        Paradigm Medical Industries, Inc.
                  (Name of Registrant as Specified in Charter)

Has  caused  this  notification  to be signed on its  behalf by the  undersigned
hereunto duly authorized.

Date:   August 15, 2006             By: /s/ Raymond P.L. Cannefax
                                           Raymond P.L. Cannefax
                                           President and Chief Executive Officer